The constant mutation of SARS-CoV-2 has led to the emergence of new variants, which call for urgent effective therapeutic interventions. The trimeric spike (S) protein of SARS-CoV-2 is highly immunogenic with the receptor-binding domain (RBD) that binds first to the cellular receptor angiotensin-converting enzyme 2 (ACE2) and is therefore the target of many neutralizing antibodies. In this study, we characterized a broadly neutralizing monoclonal antibody (mAb) 9G8, which shows potent neutralization against the authentic SARS-CoV-2 wild-type (WT), Alpha (B.1.1.7), and Delta (1.617.2) viruses. Furthermore, mAb 9G8 also displayed a prominent neutralizing efficacy in the SARS-CoV-2 surrogate virus neutralization test (sVNT) against the Epsilon (B.1.429/7), Kappa (B.1.617.1), Gamma (P.1), Beta (B.1.351), and Delta Plus (1.617.2.1) RBD variants in addition to the variants mentioned above. Based on our in vitro escape mutant studies, we proved that the mutations V483F and Y489H within the RBD were involved in ACE2 binding and caused the neutralizing evasion of the virus from mAb 9G8. The development of such a cross-reactive neutralizing antibody against majority of the SARS-CoV-2 variants provides an important insight into pursuing future therapeutic agents for the prevention and treatment of COVID-19.
【저자키워드】 SARS-CoV-2 variants, spike RBD, neutralizing epitope, escape mutant, cross-neutralizing antibody, 【초록키워드】 COVID-19, Treatment, viruses, neutralizing antibody, SARS-CoV-2, Efficacy, ACE2, Mutation, Neutralizing antibodies, B.1.351, neutralization, monoclonal antibody, variant, Delta, in vitro, virus, angiotensin-converting enzyme 2, variants, Protein, Receptor-binding domain, SARS-CoV-2 variants, B.1.1.7, RBD, P.1, Epsilon, B.1.617.1, virus neutralization test, neutralization test, Gamma, Alpha, target, Beta, therapeutic agents, Neutralizing, mutant, surrogate virus neutralization test, mAb, angiotensin, ACE2 binding, cross-reactive, treatment of COVID-19, sVNT, therapeutic interventions, immunogenic, wild-type, RBD variants, trimeric spike, cellular receptor, effective, bind, caused, involved, addition, characterized, provide, majority, the RBD, the receptor-binding domain, future therapeutic, RBD variant, the SARS-CoV-2, 【제목키워드】 SARS-CoV-2, characterization,